<DOC>
	<DOCNO>NCT00931138</DOCNO>
	<brief_summary>Randomized comparison standard induction treatment daunorubicin 3 day Idarubicin 3 4 day adult AML patient 50 70 year . Study maintenance treatment IL2</brief_summary>
	<brief_title>Treatment Acute Myeloid Leukemia ( AML ) Adults 50 70 Years , Study Two Anthracyclines Interest Maintenance Treatment With Interleukin 2</brief_title>
	<detailed_description>Patients 50 70 year de novo AML randomize receive ARAC 200 mg / m² / IV x 7 either DNR 80 mg/m²/dx3d ( arm 1 ) IDA 12 mg / m²/d x 3 ( arm 2 ) 4 ( arm 3 ) . The pt receive fail course remedial Mitoxantrone involve x 2 j ARAC 1g / 2 x / x 4 day The pt CR receive 2 course consolidation , accord initial randomization either DNR 80 mg / m² IDA 12 mg / sqm x 1 ( 1st treatment ) 2 ( 2nd treatment ) ARAC 1 gsm 2/jx x 4 day The pt CR randomize persistent IL2 ( 5 million IU / m² x 5 / month SC 12 month ) treatment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Patient 50 70 year AML de Novo No prior therapy AML Absence severe infection ( WHO grade great 2 ) , independent AML Cardiac function determine radionucleotide echography within normal limit . total bilirubin less equal 2N Serum creatinin less equal 2N ECOG performance status 0 3 Signed inform consent . M3AML history neoplasia treat radiotherapy chemotherapy Myelodysplasia diagnose 6 month diagnosis AML Prior treatment AML Uncontrolled infection Other active malignancy Patient unable undergo regular surveillance</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 1999</verification_date>
	<keyword>Acute Myeloid Leukemia adult</keyword>
	<keyword>Newly-diagnosed untreated AML</keyword>
	<keyword>Patient age 50 70 year</keyword>
</DOC>